Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Supplementary Table 2. Multinomial logistic regression models among HC users, showing the associations between levels of use of psychotropic medications (based on quantiles of redeemed DDD) between 2013 and 2016, and type of HC used in 2017.

Class of HC*	Level of use†	Model 1			Model 2			Model 3		
		RRR	95% CI	p-value	RRR	95% CI	p-value	RRR	95% CI	p-value
					Antipsychotics					
G02BA IUD with progestogen	Low	0.94	0.85 to 1.04	0.238	0.94	0.84 to 1.04	0.204	1.03	0.94 to 0.13	0.543
	Intermediate	1.18	1.05 to 1.31	0.0045	1.01	1.91 to 1.13	0.847	1.25	1.12 to 1.40	0.0001
	High	1.45	1.30 to 1.61	<0.0001	1.14	1.02 to 1.27	0.021	1.92	1.73 to 2.12	<0.0001
G02BB01 vaginal ring with progestogen and estrogen	Low	1.04	0.92 to 1.16	0.557	0.92	0.82 to 1.04	0.185	0.92	0.82 to 1.03	0.155
	Intermediate	1.08	0.95 to 1.24	0.247	1.27	1.13 to 1.42	0.0001	1.02	0.89 to 1.17	0.790
	High	0.99	0.85 to 1.14	0.838	0.90	0.78 to 1.03	0.112	1.92	1.71 to 2.15	<0.0001
G03AB Progestogens and estrogens, sequential preparations (systemic use)	Low	0.92	0.77 to 1.10	0.364	1.14	0.98 to 1.32	0.086	1.03	0.88 to 1.19	0.730
	Intermediate	1.24	1.03 to 1.49	0.023	0.88	0.73 to 1.06	0.187	0.27	0.19 to 0.38	<0.0001
	High	1.35	1.12 to 1.62	0.0016	1.03	0.87 to 1.22	0.762	0.93	0.75 to 1.15	0.487
G03AC Progestogens (systemic use)	Low	1.30	1.22 to 1.38	<0.0001	1.00	0.94 to 1.07	0.960	0.70	0.65 to 0.76	<0.0001
	Intermediate	1.46	1.36 to 1.57	<0.0001	0.96	0.89 to 1.04	0.341	1.58	1.48 to 1.70	<0.0001
	High	2.10	1.96 to 2.25	<0.0001	0.78	0.72 to 0.85	<0.0001	1.19	1.10 to 1.29	<0.0001
G03HB01 cyproterone and estrogen	Low	1.07	0.96 to 1.20	0.239	1.12	1.00 to 1.25	0.048	1.10	0.99 to 1.22	0.067
	Intermediate	1.37	1.22 to 1.54	<0.0001	0.86	0.75 to 0.98	0.028	1.43	1.28 to 1.61	<0.0001
	High	1.52	1.35 to 1.72	<0.0001	1.02	0.90 to 1.16	0.785	1.80	1.60 to 2.01	<0.0001
					Anxiolytics					
G02BA IUD with progestogen	Low	1.55	1.40 to 1.71	<0.0001	1.34	1.21 to 1.47	<0.001	1.13	1.02 to 1.25	0.018
	Intermediate	1.84	1.66 to 2.04	<0.0001	1.01	0.91 to 1.13	0.855	0.98	0.88 to 1.10	0.739
	High	1.75	1.56 to 1.96	<0.0001	0.74	0.65 to 0.84	<0.0001	1.13	1.02 to 1.26	0.026
	Low	1.67	1.49 to 1.87	<0.0001	1.41	1.27 to 1.58	<0.0001	0.88	0.78 to 1.01	0.061

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

G02BB01 vaginal ring with progestogen and estrogen	Intermediate	1.58	1.40 to 1.78	<0.0001	1.00	0.88 to 1.14	0.985	0.82	0.71 to 0.94	0.0042
	High	1.47	1.28 to 1.68	<0.0001	0.97	0.85 to 1.11	0.658	0.75	0.65 to 0.86	0.0001
G03AB Progestogens and estrogens, sequential preparations (systemic use)	Low	1.34	1.12 to 1.60	0.0014	0.60	0.48 to 0.75	<0.0001	0.86	0.71 to 1.03	0.099
	Intermediate	1.92	1.63 to 2.26	<0.0001	0.86	0.71 to 1.04	0.119	0.99	0.83 to 1.18	0.930
	High	1.93	1.62 to 2.30	<0.0001	0.97	0.80 to 1.17	0.750	0.29	0.21 to 0.40	<0.0001
G03AC Progestogens (systemic use)	Low	1.62	1.51 to 1.74	<0.0001	0.93	0.86 to 1.00	0.065	1.10	1.02 to 1.18	0.0125
	Intermediate	1.75	1.62 to 1.88	<0.0001	1.01	0.94 to 1.09	0.764	1.10	1.02 to 1.18	0.0138
	High	2.16	2.01 to 2.34	<0.0001	0.85	0.78 to 0.92	0.0001	0.86	0.79 to 0.93	0.0001
G03HB01 cyproterone and estrogen	Low	1.42	1.26 to 1.60	<0.0001	1.46	1.32 to 1.63	<0.0001	0.91	0.81 to 1.04	0.156
	Intermediate	1.68	1.49 to 1.89	<0.0001	1.14	1.01 to 1.28	0.0038	0.88	0.78 to 1.01	0.062
	High	2.04	1.81 to 2.30	<0.0001	1.63	1.46 to 1.82	<0.0001	0.62	0.53 to 0.72	<0.0001
Hypnotics/Sedatives										
G02BA IUD with progestogen	Low	1.70	1.56 to 1.85	<0.0001	0.88	0.80 to 0.97	0.010	0.70	0.64 to 0.78	<0.0001
	High	2.14	1.96 to 2.33	<0.0001	1.54	1.41 to 1.67	<0.0001	0.88	0.79 to 0.97	0.012
G02BB01 vaginal ring with progestogen and estrogen	Low	1.63	1.48 to 1.79	<0.0001	1.11	1.00 to 1.22	0.0514	1.16	1.06 to 1.28	0.0020
	High	1.70	1.52 to 1.89	<0.0001	1.00	0.89 to 1.12	0.948	1.55	1.41 to 1.71	<0.0001
G03AB Progestogens and estrogens, sequential preparations (systemic use)	Low	1.89	1.66 to 2.16	<0.0001	0.76	0.65 to 0.89	0.0008	1.27	1.12 to 1.45	0.0004
	High	2.69	2.37 to 3.06	<0.0001	1.27	1.10 to 1.46	0.0011	0.95	0.80 to 1.12	0.523
G03AC Progestogens (systemic use)	Low	1.60	1.51 to 1.70	<0.0001	1.07	1.01 to 1.14	0.0329	0.79	0.74 to 0.84	<0.0001
	High	1.93	1.81 to 2.06	<0.0001	1.06	0.99 to 1.13	0.093	1.35	1.27 to 1.44	0.007
G03HB01 cyproterone and estrogen	Low	1.48	1.34 to 1.64	<0.0001	1.10	1.00 to 1.22	0.060	0.93	0.84 to 1.03	0.138
	High	2.03	1.84 to 2.24	<0.0001	1.41	1.28 to 1.56	<0.0001	1.06	0.95 to 1.19	0.282
Antidepressants										
G02BA IUD with progestogen	Low	1.30	1.23 to 1.39	<0.0001	0.95	0.89 to 1.01	0.085	0.88	0.82 to 0.94	0.0001
	Intermediate	1.37	1.29 to 1.46	<0.0001	1.29	1.22 to 1.36	<0.0001	0.95	0.89 to 1.01	0.089

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

BMJ Open

	High	1.73	1.63 to 1.83	<0.0001	0.76	0.71 to 0.81	<0.0001	0.89	0.84 to 0.95	0.0005
G02BB01 vaginal ring with progestogen and estrogen	Low	1.40	1.31 to 1.50	<0.0001	0.89	0.83 to 0.96	0.0223	1.06	0.99 to 1.13	0.121
	Intermediate	1.31	1.22 to 1.40	<0.0001	1.00	0.93 to 1.07	0.919	1.06	0.99 to 1.14	0.102
	High	1.45	1.36 to 1.56	<0.0001	1.16	1.09 to 1.24	<0.0001	0.95	0.88 to 1.02	0.132
G03AB Progestogens and estrogens, sequential preparations (systemic use)	Low	1.46	1.33 to 1.61	<0.0001	1.00	0.91 to 1.11	0.933	1.02	0.93 to 1.13	0.664
	Intermediate	1.38	1.25 to 1.52	<0.0001	0.79	0.71 to 0.88	<0.0001	0.90	0.81 to 0.99	0.0381
	High	1.74	1.58 to 1.91	<0.0001	0.98	0.89 to 1.09	0.738	0.95	0.85 to 1.05	0.268
G03AC Progestogens (systemic use)	Low	1.49	1.44 to 1.56	<0.0001	1.00	0.96 to 1.04	0.887	0.98	0.94 to 1.02	0.387
	Intermediate	1.42	1.37 to 1.48	<0.0001	1.02	0.98 to 1.07	0.362	1.01	0.97 to 1.06	0.544
	High	1.79	1.72 to 1.87	<0.0001	0.89	0.85 to 0.93	<0.0001	0.90	0.87 to 0.94	<0.0001
G03HB01 cyproterone and estrogen	Low	1.19	1.11 to 1.28	<0.0001	0.98	0.92 to 1.05	0.609	1.00	0.93 to 1.07	0.972
	Intermediate	1.29	1.21 to 1.39	<0.0001	1.24	1.16 to 1.32	<0.0001	0.89	0.82 to 0.95	0.0011
	High	1.59	1.48 to 1.70	<0.0001	0.99	0.92 to 1.06	0.786	1.01	0.94 to 1.08	0.836

Model 1 is the unadjusted model; Model 2 is Model 1 adjusted for age, marital and socioeconomic status, education and income level; Model 3 is Model 2 adjusted for abortion and pregnancy in 2016-2017.

[*]Reference: G03AA, Progestogens and estrogens, fixed combinations (systemic use).

[†]Level of use of psychotropic medications was based on quantiles of purchased DDD (tertiles for antipsychotics, anxiolytics, antidepressants and psychostimulants; 50th percentile for hypnotics/sedatives, and 60th percentile for psycholeptics and psychoanaleptics in combination.

DDD, defined daily dose; HC, hormonal contraception; RRR, relative risk ratio.